Biocryst Pharmaceuticals (BCRX) Other Accumulated Expenses (2013 - 2021)

Biocryst Pharmaceuticals (BCRX) has 9 years of Other Accumulated Expenses data on file, last reported at $3.7 million in Q4 2021.

• Quarterly Other Accumulated Expenses fell 24.85% year-over-year to $3.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $3.7 million (down 24.85% YoY) and the FY2021 annual result came in at $3.7 million, down 24.85% from the prior year.
• Other Accumulated Expenses declined to $3.7 million in Q4 2021, from $4.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.9 million in Q4 2020 to a low of $1.8 million in Q4 2018.
• A 5-year average of $3.2 million and a median of $3.5 million in 2019 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses surged 86.54% — and 2021, when it fell 24.85%.
• Tracing BCRX's Other Accumulated Expenses over 5 years: stood at $2.2 million in 2017, then fell by 17.19% to $1.8 million in 2018, then surged by 86.54% to $3.5 million in 2019, then soared by 41.81% to $4.9 million in 2020, then slipped by 24.85% to $3.7 million in 2021.
• The last three Other Accumulated Expenses figures came in at $3.7 million (Q4 2021), $4.9 million (Q4 2020), and $3.5 million (Q4 2019), per Business Quant data.